Synthaverse S.A. (6NQ.F)

1,1160 +0,0500 (+4,69%) Al cierre: 03:29PM CEST

Synthaverse S.A.

Ul. Uniwersytecka 10
Lublin 20-029
Poland
48 81 533 8221
https://www.synthaverse.pl

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 239

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Waldemar Sierocki	Secretary of Supervisory Board & Member of Supervisory Board	24k	N/A	N/A
Mr. Mieczyslaw Starkowicz	President of the Management Board & CEO	N/A	N/A	N/A
Radoslaw Wroblewski	Chief Financial Officer	N/A	N/A	N/A
Mr. Jakub Winkler	Chief Organizational & Legal Officer and Member of the Management Board	N/A	N/A	N/A
Ms. Katarzyna Krukowoska	Chief Accountant	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2020 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company's prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerolfor is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma. In addition, the company provides reagents, such as horse serum, bovine serum, calf serum, trypsin, PBS fluid, hanks fluid, parker's fluid, Eagle 1959 medium, Rpmi 1640 medium, and Ogawa medium, as well as pseudo cholinesterase, Ox fibrinogen, and rabbit complements. The company was formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. and changed its name to Synthaverse S.A. in July 2023. The company was founded in 1944 and is based in Lublin, Poland.

Gobierno corporativo

El ISS Governance QualityScore de Synthaverse S.A., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.